Evidence map›Paper›PMID 32253827›Full record

Trial reportCancer medicine2020

Optimal treatment strategy with nilotinib for patients with newly diagnosed chronic-phase chronic myeloid leukemia based on early achievement of deep molecular response (MR

Kaichi Nishiwaki, Kei-Ji Sugimoto, Shigehisa Tamaki, Junichi Hisatake, Hisayuki Yokoyama, Tadahiko Igarashi, Atsushi Shinagawa, Takeaki Sugawara, Satoru Hara, Kazuhisa Fujikawa and 4 more

Open access · goldAbstract readClinical Trial, Phase IIMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Cancer medicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.5field-weighted citation impact, top 33% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 4 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 14 institutions in 2 countries.

Kaichi NishiwakiDivision of Oncology and Hematology, Jikei University Kashiwa Hospital, Kashiwa, Japan.ORCID 0000-0003-2188-1241
Kei-Ji SugimotoDivision of Hematology, Juntendo University Urayasu Hospital, Chiba, Japan.
Shigehisa TamakiDepartment of Hematology/Infectious Disease, Ise Red Cross Hospital, Ise, Japan.
Junichi HisatakeDepartment of Hematology, Omori Red Cross Hospital, Tokyo, Japan.
Hisayuki YokoyamaDepartment of Hematology, National Hospital Organization, Sendai Medical Center, Sendai, Japan.
Tadahiko IgarashiDivision of Hematology and Oncology, Gunma Cancer Center, Ohta, Japan.
Atsushi ShinagawaDepartment of Internal Medicine, Hitachi General Hospital, Ibaraki, Japan.
Takeaki SugawaraDivision of Hematology-Oncology, Chiba Cancer Center, Chiba, Japan.
Satoru HaraDepartment of Hematology, Chiba Rosai Hospital, Chiba, Japan.
Kazuhisa FujikawaDepartment of Hematology, Chibaken Saiseikai Narashino Hospital, Narashino, Japan.
Seiichi ShimizuDepartment of Hematology, Tsuchiura Kyodo General Hospital, Tsuchiura, Japan.
Toshiaki YujiriThird Department of Internal Medicine, Yamaguchi University, Yamaguchi, Japan.
Arinobu TojoDivision of Molecular Therapy, Institute of Medical Science, Tokyo University, Tokyo, Japan.
Hisashi WakitaDivision of Hematology and Oncology, Japanese Red Cross Society, Narita Red Cross Hospital, Narita, Japan.
Chiba Cancer Center · JPChibaken Saiseikai Narashino Hospital · JPChiba Rosai Hospital · JPGunma Children's Medical Center · JPHitachi General Hospital · JPIse Red Cross Hospital · JPJapanese Red Cross Narita Hospital · JPJikei University Kashiwa hospital · JPJuntendo University Urayasu Hospital · JPRed Cross Hospital · GRSendai Medical Center · JPTokyo Medical University · JPTsuchiura Kyodo General Hospital · JPYamaguchi University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

For patients who have chronic myeloid leukemia (CML), one of the primary treatment options is administration of nilotinib 300 mg twice daily (BID). In previous studies which compared outcomes associated with nilotinib or imatinib treatment, nilotinib achieved a higher rate of deep molecular response (MR). We conducted a phase II, open-label, multicenter study to investigate an intrapatient nilotinib dose-escalation strategy for patients with newly diagnosed chronic-phase (CP) CML based on early MR

Indexed as

AdultAgedAged, 80 and overFemaleFollow-Up StudiesHumansLeukemia, Myeloid, Chronic-PhaseMaleMiddle AgedNon-Randomized Controlled Trials as TopicPrognosisPyrimidinesSurvival RateYoung AdultnilotinibPyrimidineschronic myeloid leukemiaearly deep molecular responsenilotinib

Identifiers

PMID32253827
PMCPMC7286457
OpenAlexW3014944251

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.